RPS9A Antibody

What is RPS9A and what research applications require RPS9A antibodies?

RPS9A (Small ribosomal subunit protein uS4A) is a component of the 40S ribosomal subunit that plays a critical role in protein synthesis. It exists as one of a paralogous pair in yeast, with RPS9B being its counterpart. RPS9A antibodies are essential tools for studying:

• Ribosome biogenesis and assembly

• Translational regulation mechanisms

• Gene expression control through paralogue expression

• RNA processing and splicing regulation

• Stress response pathways involving translational machinery

Researchers typically use RPS9A antibodies in Western blotting, immunohistochemistry, immunofluorescence, and immunoprecipitation experiments to track protein expression, localization, and interactions .

How do RPS9A and RPS9B differ functionally, and how can antibodies help distinguish them?

RPS9A and RPS9B are paralogous genes encoding ribosomal proteins in yeast with distinct expression patterns despite their similar functions. Key differences include:

When designing experiments to distinguish between these paralogs, researchers can use epitope tagging approaches as demonstrated in the literature where His-tagged versions of RPS9A and RPS9B were created to directly compare expression levels using a single probe or antibody .

What are the optimal conditions for using RPS9A antibodies in various applications?

Successful application of RPS9A antibodies requires careful optimization of experimental conditions:

These recommendations are starting points based on commercial antibody specifications . Researchers should perform titration experiments to determine optimal conditions for their specific samples and experimental systems.

How should RPS9A antibody experiments be controlled to ensure specificity and reliability?

Rigorous controls are essential for RPS9A antibody experiments:

• Positive controls: Include samples known to express RPS9A (e.g., HeLa cells for human studies, wild-type yeast for yeast studies)

• Negative controls: Use corresponding genetic knockout/knockdown samples or pre-immune serum

• Cross-reactivity assessment: When working with both RPS9A and RPS9B, test antibody specificity against recombinant versions of each paralog

• Peptide competition: Pre-incubate antibody with immunizing peptide to confirm signal specificity

• Secondary antibody controls: Include secondary-only controls to assess non-specific binding

• Loading controls: Use established housekeeping proteins distinct from the ribosomal pathway

For genetic studies investigating RPS9A function, the literature describes using tagged versions (e.g., His-tagged RPS9A) that allow for direct comparison with wild-type controls while ensuring antibody specificity .

How can RPS9A antibodies be employed to study intron-mediated regulation of gene expression?

RPS9A represents an excellent model for studying intron-mediated gene regulation. Research has shown that introns significantly influence RPS9A expression through:

• Intronic structural elements: The presence of a two-way helical structure in RPS9A introns inhibits splicing efficiency

• Negative feedback regulation: The Rps9B protein preferentially binds to the RPS9A intron, creating an asymmetric feedback loop

• Differential splicing efficiency: RPS9A generates detectable quantities of unspliced pre-mRNA while RPS9B does not

Researchers can utilize RPS9A antibodies in the following methodological approaches:

• RNA immunoprecipitation (RIP): To detect protein-RNA interactions between Rps9 proteins and intronic elements

• Chromatin immunoprecipitation (ChIP): To study association of splicing factors with RPS9A chromatin

• Immunoprecipitation followed by mass spectrometry: To identify protein complexes involved in regulating RPS9A splicing

• Combined immunofluorescence and RNA FISH: To visualize co-localization of RPS9A protein with pre-mRNA transcripts

The literature demonstrates that researchers have successfully used HA-tagged antibodies coupled to magnetic beads to perform immunoprecipitation experiments that revealed differential binding of Rps9B to the RPS9A intron .

What techniques can reveal how post-translational modifications affect RPS9A function and antibody recognition?

Post-translational modifications of ribosomal proteins including RPS9A can significantly impact their function and antibody recognition:

• 2D gel electrophoresis with Western blotting: To separate differentially modified forms of RPS9A

• Phospho-specific antibodies: To detect phosphorylation states of RPS9A

• Mass spectrometry following immunoprecipitation: To identify modification sites

• Antibody epitope mapping: To determine if modifications alter antibody binding

• Differential extraction protocols: To separate nuclear, nucleolar, and cytoplasmic pools of modified RPS9A

When interpreting Western blot results showing multiple bands or unexpected molecular weights, researchers should consider:

• Whether observed molecular weight (25 kDa) differs from calculated weight (22-23 kDa) due to modifications

• If sample preparation methods (e.g., heating, reducing conditions) affect antibody recognition

• Whether cross-reactivity with other ribosomal proteins is occurring

Current research suggests the molecular weight of RPS9 is approximately 22-25 kDa, with possible variations due to post-translational modifications .

Why might Western blots with RPS9A antibodies show unexpected banding patterns, and how should these be interpreted?

Unexpected banding patterns in RPS9A Western blots can result from various factors that researchers should systematically investigate:

• Multiple bands: May indicate:

  • Post-translational modifications (phosphorylation, ubiquitination)

  • Alternative splicing variants

  • Proteolytic degradation during sample preparation

  • Cross-reactivity with RPS9B or other ribosomal proteins

• Higher molecular weight than expected: Could represent:

  • Protein complexes incompletely denatured

  • Covalently linked ubiquitin or SUMO modifications

  • Experimental artifacts from sample preparation

• Lower molecular weight than expected: Potentially indicates:

  • Proteolytic degradation during extraction

  • Alternative translation start sites

  • C-terminal processing

To systematically address these issues:

• Include positive control samples with known RPS9A expression

• Perform peptide competition assays to confirm specificity

• Vary denaturing conditions to assess complex formation

• Compare purified recombinant RPS9A alongside cellular extracts

• Test different extraction buffers with various protease inhibitors

For example, Boster Bio reports an observed molecular weight of 72 kDa for RPS9 despite a calculated molecular weight of 22.5 kDa, highlighting the importance of empirical validation .

How can researchers optimize RPS9A antibody-based immunoprecipitation for studying protein-RNA interactions?

Optimizing RPS9A antibody-based immunoprecipitation (IP) for studying protein-RNA interactions requires careful consideration of several parameters:

• Crosslinking optimization:

  • For protein-RNA interactions, use UV crosslinking (254nm) or formaldehyde (0.1-1%)

  • Titrate crosslinking time and intensity to maximize capture while minimizing artifacts

• Extraction conditions:

  • Use buffers containing RNase inhibitors

  • Optimize salt concentration (150-500mM NaCl) to maintain specific interactions

  • Consider detergent types and concentrations that preserve complexes

• Antibody selection and validation:

  • Test multiple antibodies targeting different epitopes

  • Validate IP efficiency using Western blot before proceeding to RNA analysis

  • Consider using epitope-tagged RPS9A to improve IP specificity

• Controls and data validation:

  • Include IgG control IP from the same species

  • Perform IPs from cells lacking or depleted of RPS9A

  • Include RNase-treated samples as negative controls for RNA binding

• Analysis methods:

  • qRT-PCR for known target RNAs

  • RNA-Seq for unbiased identification of bound transcripts

  • Structure probing of bound RNAs to identify binding sites

The literature describes successful RPS9 protein-RNA interaction studies using HA-antibody magnetic bead immunoprecipitation with RNase treatment as a control, followed by qPCR detection of specific RNA targets .

What strategies can distinguish between RPS9A and RPS9B function in vivo, and what role do antibodies play?

Distinguishing between RPS9A and RPS9B functions requires sophisticated experimental approaches:

• Genetic approaches:

  • Single gene deletions (rps9aΔ or rps9bΔ)

  • Domain swap experiments between paralogs

  • Promoter exchange studies

  • Intron replacement experiments

• Antibody-based approaches:

  • Epitope tagging of endogenous genes (His-tag, HA-tag)

  • Development of paralog-specific antibodies targeting divergent regions

  • Immunoprecipitation followed by mass spectrometry to identify differential binding partners

  • ChIP-seq to identify differential chromatin association

• Expression analysis:

  • RT-qPCR with paralog-specific primers

  • Ribosome profiling to assess translation effects

  • Polysome association of each paralog

Research has demonstrated that epitope tagging (e.g., His-tagging) RPS9A and RPS9B allows direct comparison of expression levels, revealing that RPS9B produces 20 times more RNA and almost 60 times more protein than RPS9A . Additionally, researchers have shown that deleting the RPS9B gene increases RPS9A expression, while deleting just the RPS9B intron inhibits RPS9A expression, suggesting complex regulatory relationships .

How applicable are commercial RPS9A antibodies across different model organisms, and what validation is required?

Cross-species applicability of RPS9A antibodies requires careful validation:

When using RPS9A antibodies across species:

• Sequence alignment validation: Compare the immunogen sequence with the target species sequence

• Epitope conservation analysis: Ensure the epitope region is conserved

• Empirical testing: Always validate with positive and negative controls from the target species

• Species-specific optimizations:

  • Adjust antibody concentrations (typically higher for less homologous species)

  • Modify blocking conditions to reduce background

  • Optimize incubation times and temperatures

Available commercial antibodies such as those from Proteintech (18215-1-AP) have been validated for human and mouse samples, with recommended dilutions provided for various applications . When working with yeast RPS9A specifically, researchers should consider that many commercial antibodies are raised against human RPS9 and may require additional validation for cross-reactivity with yeast proteins .